

Electronic Supplementary Material (ESI) for Organic Chemistry Frontiers. This Journal is © The Royal Society of Chemistry 2022

Efficient Synthesis of Benzosultams Containing Continuous Quaternary Carbons via Trapping Active Ylides with Cyclic N-Sulfonyl Ketimines

Zhengli Luo, Xuwen Chen, Jian Xue, Yaqi Deng, Suzhen Dong*, Shunying Liu*Shanghai

Engineering Research Center of Molecular Therapeutics and New Drug Development, School of

Chemistry and Chemical Engineering, East China Normal University, 3663 North Zhongshan

Road, Shanghai 200062, China

syliu@sist.ecnu.edu.cn.

Shunying Liu ORCID: 0000-0002-3894-757X

Suzhen Dong ORCID: 0000-0002-6716-6115

Contents

1. General information	2
2. Optimization of reaction conditions	3
3. General procedure	6
4. References	8
5. Characterization data for the products 4 and 6	9
6. ^1H and ^{13}C NMR spectra for products 4 and 6	24

1. General information


All ^1H NMR, ^{13}C NMR and ^{19}F NMR spectra were recorded using a Bruker 400 MHz spectrometer in CDCl_3 or CD_2Cl_2 . Tetramethylsilane (TMS) served as an internal standard ($\delta = 0$) for ^1H NMR, and CDCl_3 or CD_2Cl_2 was used as internal standard ($\delta = 77.0$ or 53.0) for ^{13}C NMR. Chemical shifts are reported in parts per million as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad). Highresolution mass spectrometry (HRMS) were recorded on IonSpec FT-ICR mass spectrometer.

Sulfimide¹ and diazo compounds² were prepared according to the literature methods. The benzyl alcohols were purchased from Sahn Chemical Technology Ltd and used without further purification. All reactions and manipulations were carried out under air atmosphere in a flame-dried or oven-dried flask containing magnetic stir bar. Dichloromethane (DCM), 1,2-dichloroethane (DCE), CHCl_3 , THF and toluene was distilled over calcium hydride. Solvents for the column chromatography were distilled before use.

The optical density at 450 nm of each well was read using a microplate reader (Molecular Devices Corporation, USA) to calculate the percent of cell viability. The inhibition rates were calculated using GraphPad Prism 8.0 software. The four tested cell lines were purchased from the Type Culture Collection of the Chinese Academy of Sciences. The media, fetal bovine serum (BI) and penicillin-streptomycin were purchased from Basal Media Technologies Co, Ltd and the cell counting kit-8 (CCK8) was purchased from Yeasen Biotech Co, Ltd.



2. Optimization of reaction conditions

Scheme S1 Optimization of reaction conditions




^a The amount ratio of **1a** : **2a** : **3a** = 1 : 1 : 1


Scheme S2 Screening of chiral ligand ^a




(*R*)-L₁: R = 2,4,6-(*i*Pr)₃C₆H₂
 (*R*)-L₂: R = C₆H₅
 (*R*)-L₃: R = SiPh₃
 (*R*)-L₄: R = Phenanthrene




L₃-PiPr₂-Ad: R = 2,4-*i*Pr₂-Ad, n = 2
 L₃-PiPr₃: R = 2,4,6-*i*Pr₃C₆H₃, n = 2
 L₃-PiEt₂Me: R = 2,6-Et₂-4-MeC₆H₂, n = 2
 L₃-PrPr₃: R = 2,4,6-*i*Pr₃C₆H₃, n = 1




G-1



G-2



L₁₁: R¹ = PAd₂, R² = Ph
 L₁₂: R¹ = PPh₂, R² = Ph
 L₁₃: R¹ = PPh₂, R² = Ph₂PCH₂
 L₁₄: R¹ = H, R² = Ph₂PCH₂
 L₁₅: R¹ = PCy₂, R² = Ph



L₁₆: R¹ = PAd₂, R² = Ph
 L₁₇: R¹ = PPh₂, R² = Ph
 L₁₈: R¹ = PCy₂, R² = Ph

L₁₉: R¹ = PAd₂, R² = Ph
 L₂₀: R¹ = PCy₂, R² = Ph


Entry	Ligand	Solvent	Yield (%) ^b	dr ^c (syn/anti)	ee ^d (%)
1	(<i>R</i>)-L1	DCM	78	1:1	0
2	(<i>R</i>)-L2	DCM	76	1:1	0
3	(<i>R</i>)-L3	DCM	76	1:1	0
4	(<i>R</i>)-L4	DCM	74	1:1	0
5	L ₃ -PrPr ₃	DCM	78	1:1	<3%

6	L₃-PiPr₂-Ad	DCM	74	1:1	<3%
7	L₃-PiEt₂Me	DCM	76	1:1	<3%
8	L₃-PiPr₃	DCM	78	1:1	<3%
9	G-1	DCM	trace	1:1	<3%
10	G-2	DCM	72	1:1	<3%
11	L11	DCM	75	1:1	<3%
12	L12	DCM	54	1:1	0
13	L13	DCM	62	1:1	0
14	L14	DCM	74	1:1	0
15	L15	DCM	78	1:1	<3%
16	L16	DCM	65	1:1	<3%
17	L17	DCM	58	1:1	<3%
18	L18	DCM	63	1:1	<3%
19	L19	DCM	67	1:1	<3%
20	L20	DCM	70	1:1	0

^a Conditions: Unless otherwise noted, all reactions were conducted on a 0.2 mmol scale of **1**, **1a** : **2a** : **3a** = 2: 3: 3. ^b Combined yield of syn- and anti-isomers after isolation. ^c Ratio of *syn/anti* diastereoisomers determined by crude ¹H NMR. ^d The ee value for **4a** determined by HPLC analysis using a chiral stationary phase.


3. General procedure

3.1 General procedure for the preparation of phenyl diazoester.¹



Under nitrogen, at room temperature, a round bottomed flask is charged with the phenylacetic acid (1 equiv.), dry DCM (0.4 M), oxalyl chloride (1.5 equiv.). Then, DMF (1 or 2 drops) is added. The reaction is allowed to stir at room temperature for 2h. Then, the reaction temperature is cooled to 0°C and an excess of alcohol (x mL) is added. The reaction is allowed to warm up to room temperature and to stir at this temperature overnight. Then, the reaction is quenched with a saturated aqueous solution of Na₂CO₃, extracted with AcOEt (3 × 30 mL), dried with MgSO₄ and concentrated under reduced pressure. The solvent was removed and the crude product was obtained used directly in the next step. To a mixture of the crude product obtained above (20 mmol) and tosyl azide (*p*-ABSA) (30 mmol) in anhydrous CH₃CN (20 mL), 1,8-diazabicyclo [5.4.0] undec-7-ene (DBU) (30 mmol) was added slowly. The reaction mixture was stirred at room temperature for overnight. Upon complete consumption of the starting materials, the reaction mixture was quenched with saturated aqueous solution of NH₄Cl (5 mL), extracted with CH₂Cl₂ (3 × 30 mL), washed by brine. The combined extracts were dried with Na₂SO₄ and concentrated. The residue was purified by flash chromatography (PE/EA, 50 :1) to afford the phenyl diazoester.

3.2 General procedure for the preparation of cyclic N-sulfonyl ketimines.²




Arylsulfonyl chloride (20 mmol) was added dropwise to a solution of *tert*-butylamine (30mmol) and triethylamine (40mmol) in dichloromethane at 0°C. The mixture was stirred at room temperature overnight. Washed with saturated sodium carbonate and brine, the organic layer

was separated and the aqueous layer was extracted with dichloromethane (3×30 mL). The combined organic extracts were dried over anhydrous sodium sulfate. The solvent was evaporated in vacuo to obtain arylsulfonamide in solid form without further purification.

Butyllithium (30.75 mmol) was added dropwise to the anhydrous tetrahydrofuran (100ml) solution of arylsulfonamide (15 mmol) within 20 minutes at 0°C under a dry nitrogen atmosphere. Stirring at 0°C for another 25 minutes, the precipitate was formed. The suspension was further cooled to -78°C, and diethyl oxalate (45 mmol) was slowly added dropwise within 20 minutes. Stir was continued for 5 minutes, the suspension was moved to room temperature and stirred for 2 hours. After the reaction is complete, the reaction was quenched with 10% HCl (60 mL), extracted with ethyl acetate (3×30 mL), and the organic phase was concentrated in vacuo to give the crude product, which was directly used in the next step.

To the crude product obtained above, toluene (30 mL) was added and the suspension was stirred at room temperature. After 5 min dissolution occurred, trifluoroacetic acid (5 equiv) was added. After 5 h the solution was concentrated and washed with saturated sodium carbonate and extracted with ethyl acetate (3×30 mL) to remove traces of trifluoroacetic acid. Purification by flash column chromatography gave the cyclic *N*-sulfonyl ketimines.

3.3 General procedure for the preparation of benzosultam (4 or 6)



To a tube charged with 1 mol% $\text{Rh}_2(\text{OAc})_4$, cyclic *N*-sulfonyl ketimine **1** (0.2mmol) and aniline **2** (0.3 mmol) in DCM (1 mL) was added directly to the tube. Diazo compound **3** (0.3 mol) in DCM (1 mL) was introduced by syringe pump over 1 h at room temperature, and the reaction solution was stirred for another 1 hour. After the reaction was completed (monitored by TLC), the crude product was purified by flash chromatography on silica gel (EtOAc / petroleum ether = 1:6 ~ 1:3) to give the pure product.

3.4 General Procedure for Cell Viability Assay.

The in vitro inhibitory effect on cell proliferation was measured using CCK-8 assay. Briefly, different kinds of cells were seeded in a 96-well plate at 2500 cells per well. After 24 h culture, 100 mL medium containing the tested compound at a certain concentration was added into each well. Seventy-two hours later, the old medium was replaced with fresh medium containing 10% CCK-8 and the cells were incubated (37°C, 5% CO₂) for another 2-4 h. The optical density at 450 nm of each well was read using a microplate reader to calculate the percent of cell viability.


4. References

- (1) S. Thurow, A. A. G. Fernandes, Y. Quevedo-Acosta, M. F. de Oliveira, M. G. de Oliveira, I. D. Jurberg, Preparation of Organic Nitrates from Aryldiazoacetates and Fe(NO₃)₃·9H₂O, *Org. Lett.*, 2019, **21**, 6909–6913.
- (2) H. Wang, T. Jiang, M. H. Xu, Simple branched sulfur-olefins as chiral ligands for Rh-catalyzed asymmetric arylation of cyclic ketimines: highly enantioselective construction of tetrasubstituted carbon stereocenters, *J. Am. Chem. Soc.*, 2013, **135**, 971–974.


5. Characterization data for the products 4 and 6

*Methyl 3-(2-methoxy-2-oxo-1-phenyl-1-(*p*-tolylamino)ethyl)-2,3-dihydrobenzo[*d*]isothiazole-3-carboxylate*

I,I-dioxide (4a). White solid, *syn/anti* isomer (1:1) ratio.





HRMS(ESI) Calcd. for C₂₅H₂₄N₂O₆S (M+Na)⁺ 503.1247, found 503.1243.



*Methyl 3-(1-(4-fluorophenyl)-2-methoxy-2-oxo-1-(*p*-tolylamino)ethyl)-2,3-dihydro-benzo[*d*]isothiazole-3-*


carboxylate I,I-dioxide (4b). White solid, *syn/anti* isomer (1:1) ratio.






syn-4b (37% yield): **1H NMR** (400 MHz, Chloroform-d) δ 8.20 (d, $J= 8.05$ Hz, 1H), 7.62 (t, $J= 7.49$ Hz, 1H), 7.54 – 7.45 (m, 2H), 7.23 – 6.98 (m, 3H), 6.83 (d, $J= 8.03$ Hz, 2H), 6.80 – 6.61 (m, 2H), 6.40 (d, $J= 8.13$ Hz, 2H), 5.87 (brs, 1H), 3.92 (s, 3H), 3.69 (s, 3H), 2.18 (s, 3H); **13C NMR** (101 MHz, Chloroform-d) δ 172.1, 171.4, 162.8 (d, $J= 248.55$ Hz), 141.4, 135.5, 132.7 (d, $J= 27.85$ Hz), 131.1, 128.9, 128.8, 127.1, 126.7 (d, $J= 3.29$ Hz), 121.3, 117.4, 113.8 (d, $J= 21.42$ Hz), 76.2, 71.6, 54.6, 52.8, 20.4. **19F NMR** (376 MHz, Chloroform-d) δ -112.9. **HRMS (ESI)** Calcd. for $C_{25}H_{23}FN_2O_6S$ ($M+Na$)⁺ 521.1153, found 521.1151.

*Methyl 3-(2-methoxy-2-oxo-1-(*p*-tolyl)-1-(*p*-tolylamino)ethyl)-2,3-dihydrobenzo[d]isothiazole-3-carboxylate 1,1-dioxide (4c).* White solid, *syn/anti* isomer (1:1) ratio.




anti-4c (43% yield): **1H NMR** (400 MHz, Chloroform-d) δ 7.77 (d, $J= 7.78$ Hz, 1H), 7.56 (t, $J= 7.54$ Hz, 1H), 7.35 (t, $J= 7.77$ Hz, 1H), 7.27 (d, $J= 6.72$ Hz, 3H), 7.10 (d, $J= 8.04$ Hz, 2H), 6.77 (d, 2H), 6.74 (brs, 1H), 6.38 (d, $J= 8.05$ Hz, 1H), 6.26 (d, $J= 8.21$ Hz, 2H), 5.51 (brs, 1H), 3.73 (s, 3H), 3.69 (s, 3H), 2.39 (s, 3H), 2.13 (s, 3H). ; **13C NMR** (101 MHz, Chloroform-d) δ 172.1, 168.2, 142.2, 139.0, 136.0, 132.5, 131.7, 130.9, 129.2, 129.1, 128.8, 128.2, 120.8, 119.6, 116.7, 74.5, 73.1, 53.8, 53.0, 21.2, 20.4. **HRMS(ESI)** Calcd. for $C_{26}H_{26}N_2O_6S$ ($M+Na$)⁺ 517.1404, found 517.1390.




syn-4c (44% yield): **1H NMR** (400 MHz, Chloroform-d) δ 8.20 (d, $J= 8.03$ Hz, 1H), 7.61 (t, $J= 7.56$ Hz, 1H), 7.53 – 7.44 (m, 2H), 7.09 (brs, 1H), 6.92 (brs, 2H), 6.87 – 6.78 (m, 4H), 6.40 (d, $J= 8.43$ Hz, 2H), 5.80 (brs, 1H), 3.91 (s, 3H), 3.68 (s, 3H), 2.21 (s, 3H), 2.17 (s, 3H); **13C NMR** (101 MHz, Chloroform-d) δ 172.9, 171.7, 141.8, 138.4, 135.5, 132.7, 132.6, 130.9, 128.8, 128.3, 127.9, 127.6, 127.3, 121.2, 117.5, 76.6, 71.8, 54.5, 52.7, 21.2, 20.4.

HRMS(ESI) Calcd. for $C_{26}H_{26}N_2O_6S$ ($M+Na$)⁺ 517.1404, found 517.1390.

*Methyl 3-(1-(4-chlorophenyl)-2-methoxy-2-oxo-1-(*p*-tolylamino)ethyl)-2,3-dihydrobenzo[d]isothiazole-3-carboxylate 1,1-dioxide (**4d**)*. White solid, *syn/anti* isomer (1:1) ratio.




anti-4d (35% yield): **1H NMR** (400 MHz, Chloroform-*d*) δ 7.80 (d, *J*= 7.76 Hz, 1H), 7.60 (t, *J*= 7.53 Hz, 1H), 7.41 – 7.35 (m, 3H), 7.28 (d, *J*= 10.20 Hz, 2H), 6.77 (d, *J*= 8.28 Hz, 2H), 6.67 (brs, 1H), 6.48 (d, *J*= 8.10 Hz, 1H), 6.22 (d, *J*= 8.40 Hz, 2H), 5.57 (brs, 1H), 3.74 (s, 3H), 3.69 (s, 3H), 2.14 (s, 3H); **13C NMR** (101 MHz, Chloroform-*d*) δ 171.6, 168.0, 141.7, 136.1, 135.2, 132.6, 132.2, 131.9, 131.1, 131.0, 129.0, 128.7, 128.5, 127.6, 121.1, 116.7, 74.3, 73.0, 54.0, 53.1, 20.4. **HRMS(ESI)** Calcd. for $C_{25}H_{23}ClN_2O_6S$ (M+Na)⁺ 537.0858, found 537.0869.




syn-4d (36% yield): **1H NMR** (400 MHz, Chloroform-*d*) δ 8.19 (d, *J*= 8.02 Hz, 1H), 7.62 (t, *J*= 8.18 Hz, 1H), 7.52 (t, *J*= 7.40 Hz, 1H), 7.48 (d, *J*= 6.96 Hz, 1H), 7.16 (brs, 1H), 7.14 – 6.93 (m, 4H), 6.83 (d, *J*= 8.32 Hz, 2H), 6.39 (d, *J*= 8.44 Hz, 2H), 5.81 (brs, 1H), 3.93 (s, 3H), 3.68 (s, 3H), 2.18 (s, 3H); **13C NMR** (101 MHz, Chloroform-*d*) δ 172.0, 171.3, 141.3, 135.5, 134.7, 132.8, 132.4, 131.2, 129.5, 129.0, 128.8, 127.1, 127.0, 121.4, 117.4, 71.5, 54.7, 52.9, 20.4. **HRMS(ESI)** Calcd. for $C_{25}H_{23}ClN_2O_6S$ (M+Na)⁺ 537.0858, found 537.0869.

*Methyl 3-(1-[1,1'-biphenyl]-4-yl)-2-methoxy-2-oxo-1-(*p*-tolylamino)ethyl)-2,3-dihydrobenzo[d]isothiazole-3-carboxylate 1,1-dioxide (**4e**)*. White solid, *syn/anti* isomer (5:1) ratio.




syn-4e (68% yield): **1H NMR** (400 MHz, Chloroform-*d*) δ 8.22 (d, *J*= 8.05 Hz, 1H), 7.62 (t, *J*= 8.06 Hz, 1H), 7.52 – 7.46 (m, 3H), 7.43 (d, *J*= 7.60 Hz, 1H), 7.38 – 7.34 (m, 2H), 7.31 – 7.25 (m, 3H), 7.15 (s, 2H), 6.83 (d, *J*= 8.32 Hz, 2H), 6.46 (d, *J*= 8.43 Hz, 2H), 5.84 (brs, 1H), 3.92 (s, 3H), 3.71 (s, 3H), 2.17 (s, 3H); **13C NMR** (101 MHz, Chloroform-*d*) δ 172.5, 171.6, 141.7, 141.0, 140.3, 135.6, 132.7, 132.6, 131.0, 130.0, 128.9, 128.6, 128.5, 127.4, 127.3, 127.1, 125.3, 121.3, 117.5, 76.6, 71.8, 54.6, 52.8, 20.4. **HRMS(ESI)** Calcd. for $C_{31}H_{28}N_2O_6S$ (M+Na)⁺ 579.1560, found 579.1560.


*Methyl 3-(1-([1,1'-biphenyl]-4-yl)-2-(benzylxy)-2-oxo-1-(*p*-tolylamino)ethyl)-5-methyl-2,3-dihydrobenzo[d]isothiazole-3-carboxylate 1,1-dioxide (**4f**)*. White solid, *syn/anti* isomer (5:1) ratio.




*Methyl 3-(1-([1,1'-biphenyl]-4-yl)-2-ethoxy-2-oxo-1-(*p*-tolylamino)ethyl)-5-methyl-2,3-dihydrobenzo[d]isothiazole-3-carboxylate 1,1-dioxide (**4g**)*. White solid, *syn/anti* isomer (5:1) ratio.



*Methyl 3-(1-([1,1'-biphenyl]-4-yl)-2-isopropoxy-2-oxo-1-(*p*-tolylamino)ethyl)-5-methyl-2,3-dihydrobenzo[d]isothiazole-3-carboxylate 1,1-dioxide (**4h**)*. White solid, *syn/anti* isomer (5:1) ratio.




*Methyl 3-(1-([1,1'-biphenyl]-4-yl)-2-(tert-butoxy)-2-oxo-1-(*p*-tolylamino)ethyl)-5-methyl-2,3-dihydrobenzo[d]isothiazole-3-carboxylate 1,1-dioxide (**4i**)*. White solid, *syn/anti* isomer (6:1) ratio.




127.7, 127.1, 125.6, 120.5, 117.1, 84.3, 74.2, 73.4, 53.6, 27.7, 21.8, 20.4. **HRMS(ESI)** Calcd. for C₃₅H₃₆N₂O₆S (M+Na)⁺ 635.2186, found 635.2181.

*Methyl 3-(1-((4-chlorophenyl)amino)-2-methoxy-2-oxo-1-phenylethyl)-5-methyl-2,3-dihydrobenzo[d]isothiazole-3-carboxylate 1,1-dioxide (**4j**)*. White solid, *syn/anti* isomer (1:1) ratio.




74.4, 73.6, 53.9, 53.1, 21.7. **HRMS(ESI)** Calcd. for C₂₅H₂₃ClN₂O₆S (M+Na)⁺ 537.0858, found 537.0823.




74.4, 73.6, 53.9, 53.1, 21.7. **HRMS(ESI)** Calcd. for C₂₅H₂₃ClN₂O₆S (M+Na)⁺ 537.0858, found 537.0823.

*Methyl 3-(1-((4-chlorophenyl)amino)-2-methoxy-2-oxo-1-phenylethyl)-2,3-dihydrobenzo[d]isothiazole-3-carboxylate 1,1-dioxide (**4k**)*. White solid, *syn/anti* isomer (1:1) ratio.





131.8, 131.7, 131.1, 130.9, 129.3, 129.0, 128.1, 127.6, 123.8, 121.0, 118.0, 74.4, 73.6, 53.9, 53.2. **HRMS(ESI)**

Calcd. for $C_{24}H_{21}ClN_2O_6S$ ($M+Na$)⁺ 523.0701, found 523.0701.



71.5, 54.6, 52.9. **HRMS(ESI)** Calcd. for $C_{24}H_{21}ClN_2O_6S$ ($M+Na$)⁺ 523.0701, found 523.0701.


Methyl-3-(1-((4-chlorophenyl)amino)-2-methoxy-2-oxo-1-phenylethyl)-5-(trifluoromethyl)-2,3-dihydrobenzo[d]isothiazole-3-carboxylate 1,1-dioxide (4l). White solid, *syn/anti* isomer (1:1) ratio.



HRMS(ESI) Calcd. for $C_{25}H_{20}ClF_3N_2O_6S$ ($M+Na$)⁺ 591.0575, found 591.0561.

Methyl-3-(1-((4-chlorophenyl)amino)-2-methoxy-1-phenylethyl)-5-phenyl-2,3-dihydrobenzo[d]isothiazole-3-carboxylate 1,1-dioxide (4m).


White solid, *syn/anti* isomer (5:1) ratio.




syn-4m (76% yield): **¹H NMR** (400 MHz, Chloroform-*d*) δ 8.31 (brs, 1H), 7.71 (d, *J*= 8.00 Hz, 1H), 7.59 (d, *J*= 7.18 Hz, 2H), 7.54 – 7.46 (m, 4H), 7.38 (s, 1H), 7.23 – 7.18 (m, 1H), 7.17 – 6.99 (m, 4H), 6.96 (d, *J*= 8.70 Hz, 2H), 6.44 (d, *J*= 8.72 Hz, 2H), 5.88 (brs, 1H), 3.93 (s, 3H), 3.73 (s, 3H); **¹³C NMR** (101 MHz, Chloroform-*d*) δ 172.4, 171.8, 146.2, 142.8, 139.0, 134.1, 133.1, 130.4, 130.2, 129.3, 128.9, 128.9, 128.2, 127.5, 125.4, 124.1, 121.6, 118.7, 76.7, 71.5, 54.7, 52.9. **HRMS(ESI)** Calcd. for C₃₀H₂₅ClN₂NaO₆S (M+Na)⁺ 599.1014, found 599.0997.

Methyl 3-(1-(4-bromophenyl)-2-methoxy-1-((4-methoxyphenyl)amino)-2-oxoethyl)-2,3-dihydrobenzo[d]isothiazole-3-carboxylate 1,1-dioxide (4n).

White solid, *syn/anti* isomer (1:1) ratio.




anti-4n (44% yield): **¹H NMR** (400 MHz, Chloroform-*d*) δ 7.80 (d, *J*= 7.79 Hz, 1H), 7.60 (t, *J*= 7.58 Hz, 1H), 7.46 – 7.38 (m, 3H), 7.30 (d, *J*= 8.33 Hz, 2H), 6.68 (brs, 1H), 6.54 (d, *J*= 8.85 Hz, 2H), 6.47 (d, *J*= 8.10 Hz, 1H), 6.27 (d, *J*= 8.86 Hz, 2H), 5.45 (brs, 1H), 3.75 (s, 3H), 3.69 (s, 3H), 3.65 (s, 3H); **¹³C NMR** (101 MHz, Chloroform-*d*) δ 171.6, 168.0, 153.1, 137.8, 136.1, 132.9, 132.3, 131.9, 131.6, 131.1, 130.6, 128.6, 123.6, 121.1, 118.1, 113.8, 74.3, 73.3, 55.4, 54.0, 53.1. **HRMS(ESI)** Calcd. for C₂₅H₂₃BrN₂O₇S (M+Na)⁺ 597.0302, found 597.0337.




syn-4n (46% yield): **¹H NMR** (400 MHz, Chloroform-*d*) δ 8.20 (d, *J*= 8.00 Hz, 1H), 7.63 (t, *J*= 7.09 Hz, 1H), 7.53 (d, *J*= 7.66 Hz, 1H), 7.48 (t, *J*= 7.44 Hz, 1H), 7.16 (s, 2H), 7.10 – 7.01 (m, 3H), 6.61 (d, *J*= 8.95 Hz, 2H), 6.45 (d, *J*= 8.95 Hz, 2H), 5.85 (brs, 1H), 3.93 (s, 3H), 3.68 (s, 3H), 3.65 (s, 3H); **¹³C NMR** (101 MHz, Chloroform-*d*) δ 171.9, 171.3, 153.4, 137.5, 135.4, 132.8, 132.4, 131.2, 130.3, 127.2, 123.1, 121.4, 118.9, 113.9, 76.8, 71.4, 55.5, 54.7, 52.8. **HRMS(ESI)** Calcd. for C₂₅H₂₃BrN₂O₇S (M+H)⁺ 597.0302, found 597.0337.



Methyl 3-(1-(4-bromophenyl)-1-((4-chlorophenyl)amino)-2-methoxy-2-oxoethyl)-2,3-dihydrobenzo[d]isothiazole-3-carboxylate 1,1-dioxide (4o). White solid, *syn/anti* isomer (1:1) ratio.



HRMS(ESI) Calcd. For $C_{24}H_{20}BrClN_2O_6S$ ($M+Na$)⁺ 600.9806, found 600.9803.




Methyl 3-(1-(4-bromophenyl)-2-methoxy-2-oxo-1-(phenylamino)ethyl)-2,3-dihydrobenzo[d]isothiazole-3-carboxylate 1,1-dioxide (4p). White solid, *syn/anti* isomer (1:1) ratio.



HRMS(ESI) Calcd. for $C_{24}H_{21}BrN_2O_6S$ ($M+Na$)⁺ 567.0196, found 567.0202.

*Methyl 3-(1-(4-bromophenyl)-2-methoxy-2-oxo-1-(*p*-tolylamino)ethyl)-2,3-dihydrobenzo[d]isothiazole-*


4-carboxylate 1,1-dioxide (4q). White solid, *syn/anti* isomer (1:1) ratio.



anti-4q

anti-4q (43% yield): ¹H NMR (400 MHz, Chloroform-*d*) δ 7.80 (d, *J*= 7.74 Hz, 1H), 7.60 (t, *J*= 7.57 Hz, 1H), 7.45 – 7.38 (m, 3H), 7.30 (d, *J*= 8.32 Hz, 2H), 6.77 (d, *J*= 7.99 Hz, 2H), 6.69 (brs, 1H), 6.47 (d, *J*= 8.08 Hz, 1H), 6.22 (d, *J*= 7.99 Hz, 2H), 5.57 (brs, 1H), 3.75 (s, 3H), 3.69 (s, 3H), 2.14 (s, 3H); ¹³C NMR (101 MHz, Chloroform-*d*) δ 171.6, 168.0, 141.7, 136.0, 132.9, 132.2, 132.0, 131.6, 131.1, 130.6, 129.0, 128.7, 128.5, 123.6, 121.2, 116.7,

74.2, 73.0, 54.1, 53.2, 20.4. HRMS(ESI) Calcd. for C₂₅H₂₃BrN₂O₆S (M+Na)⁺ 581.0352, found 581.0336.




syn-4q

syn-4q (44% yield): ¹H NMR (400 MHz, Chloroform-*d*) δ 8.18 (d, *J*= 8.00 Hz, 1H), 7.62 (t, *J*= 7.45 Hz, 1H), 7.55 – 7.47 (m, 2H), 7.24 – 7.10 (m, 3H), 7.02 (brs, 2H), 6.83 (d, *J*= 8.13 Hz, 2H), 6.39 (d, *J*= 8.44 Hz, 2H), 5.82 (brs, 1H), 3.92 (s, 3H), 3.68 (s, 3H), 2.18 (s, 3H); ¹³C NMR (101 MHz, Chloroform-*d*) δ 171.9, 171.3, 141.3, 135.4, 132.9, 132.4, 131.2, 130.1, 130.0, 129.0, 128.9, 127.1, 123.1, 121.4, 117.4, 76.3, 71.4, 54.7, 52.9, 20.4. HRMS(ESI)

Calcd. for C₂₅H₂₃BrN₂O₆S (M+Na)⁺ 581.0352, found 581.0336.

*Methyl 3-(1-([1,1'-biphenyl]-4-yl)-2-methoxy-2-oxo-1-(*p*-tolylamino)ethyl)-5-phenyl-2,3-dihydrobenzo[d]isothiazole-3-carboxylate 1,1-dioxide (4r).* White solid, *syn/anti* isomer (5:1) ratio.



syn-4r


syn-4r (87% yield): ¹H NMR (400 MHz, Chloroform-*d*) δ 8.36 (brs, 1H), 7.67 (d, *J*= 8.05 Hz, 1H), 7.59 (d, *J*= 7.18 Hz, 2H), 7.53 – 7.45 (m, 6H), 7.36 (t, *J*= 7.50 Hz, 2H), 7.33 – 7.22 (m, 5H), 7.19 (s, 1H), 6.85 (d, *J*= 8.18 Hz, 2H), 6.50 (d, *J*= 8.29 Hz, 2H), 5.88 (brs, 1H), 3.94 (s, 3H), 3.72 (s, 3H), 2.18 (s, 3H); ¹³C NMR (101 MHz, Chloroform-*d*) δ 172.4, 171.5, 146.1, 141.8, 141.0, 140.3, 139.1, 134.1, 130.0, 129.3,

129.0, 128.9, 128.7, 127.5, 127.4, 127.1, 125.6, 125.4, 121.5, 117.6, 76.6, 71.8, 54.6, 52.8, 20.4. HRMS(ESI)

Calcd. for C₃₇H₃₂N₂O₆S (M+Na)⁺ 655.1873, found 655.1869.


Methyl 3-(1-(4-bromophenyl)-1-((2-chlorophenyl)amino)-2-methoxy-2-oxoethyl)-5-methyl-2,3-dihydrobenzo

5-[d]isothiazole-3-carboxylate 1,1-dioxide (4s). White solid, 73% yield, *syn/anti* isomer (1:1) ratio.



anti-4s: **¹H NMR** (400 MHz, Methylene Chloride-*d*₂) δ 7.71 (d, *J*= 7.92 Hz, 1H), 7.50 (d, *J*= 8.31 Hz, 2H), 7.46 (d, *J*= 7.89 Hz, 1H), 7.28 (d, *J*= 7.87 Hz, 2H), 6.94 (d, *J*= 8.06 Hz, 2H), 6.61 (brs, 1H), 6.27 (d, *J*= 8.05 Hz, 2H), 6.17 (s, 1H), 5.77 (brs, 1H), 3.79 (s, 3H), 3.74 (s, 3H), 2.28 (s, 3H); **¹³C NMR** (101 MHz, Methylene Chloride-*d*₂) δ 171.0, 167.9, 143.1, 133.4, 132.9, 132.2, 132.1, 131.3, 130.4, 129.0, 128.1, 123.7, 123.6, 120.6, 117.9,


74.2, 73.2, 54.0, 53.1, 21.5. **HRMS(ESI)** Calcd. for C₂₅H₂₂BrClN₂O₆S (M+Na)⁺ 614.9963, found 614.9927.



syn-4s: **¹H NMR** (400 MHz, Chloroform-*d*) δ 7.86 (s, 1H), 7.39 – 7.31 (m, 3H), 7.18 (s, 2H), 7.03 – 6.93 (m, 3H), 6.42 (d, *J*= 8.18 Hz, 2H), 5.83 (brs, 1H), 3.92 (s, 3H), 3.69 (s, 3H), 2.49 (s, 3H); **¹³C NMR** (101 MHz, Chloroform-*d*) δ 171.5, 171.5, 144.1, 142.5, 132.9, 132.4, 132.2, 129.7, 128.3, 126.9, 124.4, 123.3, 121.3, 118.6, 76.2, 71.0, 54.7, 53.0, 22.1. **HRMS(ESI)** Calcd. for C₂₅H₂₂BrClN₂O₆S (M+Na)⁺ 614.9963, found


614.9927.

Methyl 3-(1-(4-bromophenyl)-1-((4-chlorophenyl)amino)-2-methoxy-2-oxoethyl)-5-methyl-2,3-dihydrobenzo[d]isothiazole-3-carboxylate 1,1-dioxide (4t). White solid, 78% yield, *syn/anti* isomer (1:1) ratio.



anti-4t: **¹H NMR** (400 MHz, Chloroform-*d*) δ 7.73 (s, 1H), 7.67 (d, *J*= 7.94 Hz, 1H), 7.58 (d, *J*= 8.24 Hz, 2H), 7.50 – 7.43 (m, 3H), 7.30 (d, *J*= 7.83 Hz, 1H), 6.81 (t, *J*= 7.73 Hz, 1H), 6.65 (t, *J*= 7.54 Hz, 1H), 6.49 (brs, 1H), 6.02 (d, *J*= 8.17 Hz, 1H), 5.95 (brs, 1H), 3.66 (s, 3H), 3.46 (s, 3H), 2.51 (s, 3H); **¹³C NMR** (101 MHz, Chloroform-*d*) δ 168.6, 167.8, 144.0, 140.2, 133.6, 133.2, 132.4, 132.2, 132.0, 131.0, 129.4, 128.4, 127.3, 123.7, 121.2, 121.1, 119.5, 115.1, 73.4, 72.7, 54.5, 53.3, 22.1. **HRMS(ESI)** Calcd. for C₂₅H₂₂BrClN₂O₆S (M+Na)⁺

614.9963, found 614.9978.




syn-4t: **¹H NMR** (400 MHz, Chloroform-*d*) δ 8.20 (brs, 1H), 7.79 (s, 1H), 7.38 (d, *J*= 7.99 Hz, 1H), 7.35 – 7.30 (m, 2H), 7.26 (s, 2H), 6.75 (t, *J*= 7.74 Hz, 1H), 6.65 (t, *J*= 7.56 Hz, 1H), 6.07 (d, *J*= 8.25 Hz, 1H), 5.81 (brs, 1H), 3.96 (s, 3H), 3.76 (s, 3H), 2.50 (s, 3H); **¹³C NMR** (101 MHz, Chloroform-*d*) δ 171.6, 171.1, 144.0, 140.1, 133.1, 132.3, 132.1, 129.3, 129.1, 127.6, 126.4, 123.3, 121.7, 121.2, 119.2, 117.5, 75.5, 71.6, 54.8, 53.2, 22.1.

HRMS(ESI) Calcd. for C₂₅H₂₂BrClN₂O₆S (M+Na)⁺ 614.9963, found 614.9978.

Methyl 3-(2-methoxy-1-((4-methylbenzyl)oxy)-2-oxo-1-phenylethyl)-2,3-dihydrobenzo[d]isothiazole-3-carboxylate 1,1-dioxide (6a).


White solid, *syn/anti* isomer (10:1) ratio.



syn-6a (50% yield): **¹H NMR** (400 MHz, Chloroform-*d*) δ 8.10 (t, *J* = 4.90, 3.26 Hz, 1H), 7.74 (t, *J* = 4.72, 3.30 Hz, 1H), 7.66 – 7.61 (m, 2H), 7.61 – 7.57 (m, 2H), 7.43 – 7.37 (m, 3H), 7.28 (d, *J* = 7.72 Hz, 2H), 7.21 (d, *J* = 7.72 Hz, 2H), 5.81 (brs, 1H), 4.57 (d, *J* = 11.41 Hz, 1H), 4.34 (d, *J* = 11.42 Hz, 1H), 3.54 (s, 6H), 2.39 (s, 3H); **¹³C NMR** (101 MHz, Chloroform-*d*) δ 168.0, 167.8, 137.5, 135.8, 134.4, 134.2, 133.6, 132.4, 130.3, 129.7, 129.3, 129.2, 128.8, 128.0, 127.1, 120.6, 89.1, 73.6, 68.7, 53.9, 52.6, 21.2. **HRMS(ESI)** Calcd. for C₂₆H₂₅NO₇S (M+Na)⁺ 518.1244, found 518.1244.

Methyl 3-(1-(benzyloxy)-2-methoxy-2-oxo-1-phenylethyl)-2,3-dihydrobenzo[d]isothiazole-3-carboxylate 1,1-dioxide (6b).


White solid, *syn/anti* isomer (9:1) ratio.



syn-6b (51.5% yield): **¹H NMR** (400 MHz, Chloroform-*d*) δ 8.10 (t, *J* = 4.48, 3.82 Hz, 1H), 7.74 (t, *J* = 4.08 Hz, 1H), 7.64 – 7.58 (m, 4H), 7.43 – 7.38 (m, 7H), 5.82 (brs, 1H), 4.63 (d, *J* = 11.71 Hz, 1H), 4.39 (d, *J* = 11.70 Hz, 1H), 3.55 (s, 3H), 3.53 (s, 3H); **¹³C NMR** (101 MHz, Chloroform-*d*) δ 168.0, 167.8, 137.3, 135.8, 134.3, 133.5, 132.4, 130.4, 129.7, 129.3, 128.8, 128.5, 128.1, 127.8, 127.0, 120.7, 89.2, 73.6, 68.7, 53.9, 52.6. **HRMS(ESI)** Calcd. for C₂₅H₂₃NO₇S (M+Na)⁺ 504.1087, found 504.1070.

Methyl 3-(1-((4-chlorobenzyl)oxy)-2-methoxy-2-oxo-1-phenylethyl)-2,3-dihydrobenzo[d]isothiazole-3-carboxylate 1,1-dioxide (6c).


White solid, *syn/anti* isomer (10:1) ratio.



syn-6c (59.7% yield): **¹H NMR** (400 MHz, Chloroform-*d*) δ 7.96 (d, *J* = 7.41 Hz, 1H), 7.75 (d, *J* = 7.39 Hz, 1H), 7.64 – 7.57 (m, 2H), 7.57 – 7.52 (m, 2H), 7.44 – 7.39 (m, 3H), 7.37 (d, *J* = 8.25 Hz, 2H), 7.31 (d, *J* = 8.22 Hz, 2H), 5.84 (brs, 1H), 4.56 (d, *J* = 11.96 Hz, 1H), 4.39 (d, *J* = 11.95 Hz, 1H), 3.56 (s, 6H); **¹³C NMR** (101 MHz, Chloroform-*d*) δ 168.1, 167.7, 136.0, 135.8, 134.2, 133.5, 133.3, 132.4, 130.5, 129.4, 129.4, 128.8, 128.7, 128.4, 128.1, 120.8, 89.3, 73.6, 68.1, 54.0, 52.7. **HRMS(ESI)** Calcd. for C₂₅H₂₂ClNO₇S (M+Na)⁺ 538.0698, found 538.0725.

Methyl 3-(1-((4-bromobenzyl)oxy)-2-methoxy-2-oxo-1-phenylethyl)-2,3-dihydrobenzo[d]isothiazole-3-carboxylate 1,1-dioxide (6d).


White solid, *syn/anti* isomer (10:1) ratio.



syn-6d (62% yield): **¹H NMR** (400 MHz, Chloroform-*d*) δ 7.95 (d, *J*= 7.43 Hz, 1H), 7.75 (d, *J*= 7.37 Hz, 1H), 7.64 – 7.57 (m, 2H), 7.57 – 7.53 (m, 2H), 7.52 (d, *J*= 8.20 Hz, 2H), 7.43 – 7.37 (m, 3H), 7.25 (d, *J*= 8.82 Hz, 2H), 5.84 (brs, 1H), 4.54 (d, *J*= 12.00 Hz, 1H), 4.38 (d, *J*= 12.01 Hz, 1H), 3.56 (s, 6H); **¹³C NMR** (101 MHz, Chloroform-*d*) δ 168.1, 167.6, 136.3, 136.0, 134.2, 133.3, 132.3, 131.7, 130.5, 129.4, 129.4, 128.8, 128.7, 128.1, 120.8, 89.3, 73.6, 68.1, 53.9, 52.7. **HRMS(ESI)** Calcd. for C₂₅H₂₂BrNO₇S (M+Na)⁺ 582.0193, found 582.0174.

Methyl 3-(1,2-dimethoxy-2-oxo-1-phenylethyl)-2,3-dihydrobenzo[d]isothiazole-3-carboxylate 1,1-dioxide (6e).


White solid, *syn/anti* isomer (8:1) ratio.



syn-6e (62.5% yield): **¹H NMR** (400 MHz, Chloroform-*d*) δ 7.97 (d, *J*= 7.37 Hz, 1H), 7.73 (d, *J*= 6.97 Hz, 1H), 7.65 – 7.55 (m, 4H), 7.45 – 7.37 (m, 3H), 5.86 (brs, 1H), 3.59 (s, 3H), 3.55 (s, 3H), 3.34 (s, 3H); **¹³C NMR** (101 MHz, Chloroform-*d*) δ 168.0, 167.8, 135.8, 134.3, 133.4, 132.4, 130.3, 129.4, 129.2, 128.9, 127.9, 120.6, 89.3, 73.6, 54.9, 53.9, 52.6. **HRMS(ESI)** Calcd. for C₁₉H₁₉NO₇S₃ (M+Na)⁺ 428.0774, found 428.0751.

Methyl 3-(1-ethoxy-2-methoxy-2-oxo-1-phenylethyl)-2,3-dihydrobenzo[d]isothiazole-3-carboxylate 1,1-dioxide (6f).


White solid, *syn/anti* isomer (9:1) ratio.



syn-6f (74.3% yield): **¹H NMR** (400 MHz, Chloroform-*d*) δ 8.05 (d, *J*= 7.73 Hz, 1H), 7.73 (d, *J*= 7.19 Hz, 1H), 7.65 – 7.58 (m, 2H), 7.59 – 7.54 (m, 2H), 7.43 – 7.37 (m, 3H), 5.83 (brs, 1H), 3.56(s, 3H), 3.55 (q, *J*= 9.51 Hz, 1H), 3.54(s, 3H), 3.28 (q, *J*= 7.96, 7.51 Hz, 1H), 1.34 (t, *J*= 6.90 Hz, 3H); **¹³C NMR** (101 MHz, Chloroform-*d*) δ 168.2, 167.9, 135.8, 134.5, 134.0, 132.2, 130.2, 129.5, 129.1, 128.7, 127.9, 120.6, 88.8, 73.6, 62.5, 53.8, 52.5, 15.1. **HRMS(ESI)** Calcd. for C₂₀H₂₁NO₇S (M+Na)⁺ 442.0931, found 442.0936.

Methyl 3-(1-isopropoxy-2-methoxy-2-oxo-1-phenylethyl)-2,3-dihydrobenzo[d]isothiazole-3-carboxylate


1,1-dioxide (6g). White solid, *syn/anti* isomer (9:1) ratio.



syn-6g (74% yield): **¹H NMR** (400 MHz, Chloroform-*d*) δ 8.16 (d, *J*= 7.74 Hz, 1H), 7.72 (d, *J*= 7.31 Hz, 1H), 7.64 – 7.56 (m, 4H), 7.41 – 7.35 (m, 3H), 5.65 (brs, 1H), 3.94 – 3.85 (m, 1H), 3.54 (s, 3H), 3.53 (s, 3H), 1.31 (d, *J*= 6.09 Hz, 3H), 1.06 (d, *J*= 5.92 Hz, 3H); **¹³C NMR** (101 MHz, Chloroform-*d*) δ 168.8, 168.0, 135.8, 135.1, 132.2, 130.1, 129.5, 129.1, 128.9, 127.6, 120.5, 88.8, 73.8, 70.5, 53.8, 52.3, 24.5, 22.5. **HRMS(ESI)** Calcd. for C₂₁H₂₃NO₇S₃ (M+Na)⁺ 456.1087, found 456.1054.

Methyl 3-(1-(cyclopentyloxy)-2-methoxy-2-oxo-1-phenylethyl)-2,3-dihydrobenzo[d]isothiazole-3-carboxylate


1,1-dioxide (6h). White solid, *syn/anti* isomer (10:1) ratio.



syn-6h (81.7% yield): **¹H NMR** (400 MHz, Chloroform-*d*) δ 8.09 (d, *J*= 7.50 Hz, 1H), 7.73 (d, *J*= 7.05 Hz, 1H), 7.64 – 7.56 (m, 2H), 7.55 – 7.48 (m, 2H), 7.41 – 7.35 (m, 3H), 5.68 (brs, 1H), 4.15 – 4.07 (m, 1H), 3.53 (s, 6H), 2.08 – 1.95 (m, 1H), 1.96 – 1.86 (m, 1H), 1.87 – 1.76 (m, 1H), 1.75 – 1.66 (m, 1H), 1.54 – 1.39 (m, 4H); **¹³C NMR** (101 MHz, Chloroform-*d*) δ 169.0, 167.9, 135.8, 135.4, 135.1, 132.1, 130.1, 129.3, 129.0, 129.0, 127.8, 120.6, 89.1, 79.2, 73.5, 53.8, 52.4, 34.6, 32.2, 24.2, 23.7. **HRMS(ESI)** Calcd. for C₂₃H₂₅NO₇S (M+Na)⁺ 482.1244 , found 482.1222.

Methyl 3-(1-(cyclohexyloxy)-2-methoxy-2-oxo-1-phenylethyl)-2,3-dihydrobenzo[d]isothiazole-3-carboxylate


1,1-dioxide (6i). White solid, *syn/anti* isomer (10:1) ratio.



syn-6i (78% yield): **¹H NMR** (400 MHz, Chloroform-*d*) δ 8.20 (d, *J*= 7.79 Hz, 1H), 7.72 (d, *J*= 7.48 Hz, 1H), 7.65 – 7.56 (m, 4H), 7.40 – 7.35 (m, 3H), 5.64 (brs, 1H), 3.62 – 3.49 (m, 1H), 3.54(s, 3H), 3.51(s, 3H), 1.94 (d, *J*= 12.17 Hz, 1H), 1.83 – 1.72 (m, 1H), 1.65 – 1.58 (m, 3H), 1.53 – 1.43 (m, 1H), 1.38 – 1.27 (m, 1H), 1.24 (d, *J*= 10.63 Hz, 3H), 1.18 – 1.07 (m, 1H); **¹³C NMR** (101 MHz, Chloroform-*d*) δ 168.9, 168.0, 135.8, 135.8, 135.1, 132.1, 130.1, 129.6, 129.1, 129.0, 127.6, 120.5, 88.8, 76.2, 73.9, 53.8, 52.2, 34.4, 32.4, 25.4, 24.4, 24.1. **HRMS(ESI)** Calcd. for C₂₄H₂₇NO₇S (M+Na)⁺ 496.1400, found 496.1401.

Methyl 3-(2-methoxy-1-((4-methylbenzyl)oxy)-2-oxo-1-phenylethyl)-2,3-dihydrobenzo[d]isothiazole-3-carboxylate 1,1-dioxide (6j).


White solid, *syn/anti* isomer (10:1) ratio.



syn-6j (51.7% yield): **¹H NMR** (400 MHz, Chloroform-*d*) δ 7.83 (s, 1H), 7.66 – 7.58 (m, 3H), 7.44 – 7.37 (m, 4H), 7.27 (d, *J*= 7.87 Hz, 2H), 7.21 (d, *J*= 7.79 Hz, 2H), 5.81 (brs, 1H), 4.58 (d, *J*= 11.23 Hz, 1H), 4.29 (d, *J*= 11.19 Hz, 1H), 3.55 (s, 3H), 3.51 (s, 3H), 2.43 (s, 3H), 2.40 (s, 3H); **¹³C NMR** (101 MHz, Chloroform-*d*) δ 167.9, 143.1, 137.6, 134.5, 134.2, 133.7, 133.2, 131.3, 130.1, 129.2, 129.2, 128.9, 128.0, 127.4, 120.3, 89.1, 73.5, 68.8, 53.9, 52.6, 22.0, 21.3. **HRMS(ESI)** Calcd. for C₂₆H₂₅NO₇S (M+Na)⁺ 532.1400, found 532.1392.

Methyl 3-(1-ethoxy-2-methoxy-2-oxo-1-phenylethyl)-2,3-dihydrobenzo[d]isothiazole-3-carboxylate 1,1-dioxide (6k).


White solid, *syn/anti* isomer (10:1) ratio.



syn-6k (63.8% yield): **¹H NMR** (400 MHz, Chloroform-*d*) δ 7.70 (s, 1H), 7.60 (d, *J*= 7.96 Hz, 1H), 7.56 – 7.50 (m, 2H), 7.44 – 7.36 (m, 4H), 5.85 (brs, 1H), 3.59 (s, 3H), 3.56 (q, *J*= 22.63 Hz, 1H), 3.53 (s, 3H), 3.28 (q, *J*= 7.38 Hz, 1H), 2.47 (s, 3H), 1.33 (t, *J*= 6.91 Hz, 3H); **¹³C NMR** (101 MHz, Chloroform-*d*) δ 168.3, 168.0, 143.0, 134.6, 134.1, 133.2, 131.2, 129.7, 129.0, 128.8, 127.8, 120.3, 88.7, 73.5, 62.5, 53.8, 52.6, 22.1, 15.1. **HRMS(ESI)** Calcd. For C₂₀H₂₁NO₇S (M+Na)⁺ 456.1087, found 456.1081.

Methyl 3-(1-(4-chlorophenyl)-1,2-dimethoxy-2-oxoethyl)-2,3-dihydrobenzo[d]isothiazole-3-carboxylate 1,1-dioxide (6l).


White solid, *syn/anti* isomer (10:1) ratio.



syn-6l (63% yield): **¹H NMR** (400 MHz, Chloroform-*d*) δ 7.97 (d, *J*= 7.37 Hz, 1H), 7.73 (d, *J*= 7.00 Hz, 1H), 7.67 – 7.58 (m, 2H), 7.53 (d, *J*= 8.26 Hz, 2H), 7.38 (d, *J*= 8.31 Hz, 2H), 5.85 (brs, 1H), 3.59 (s, 6H), 3.31 (s, 3H); **¹³C NMR** (101 MHz, Chloroform-*d*) δ 167.8, 167.7, 135.8, 135.4, 134.1, 132.5, 132.0, 130.5, 129.3, 128.1, 120.7, 89.0, 73.5, 54.9, 54.0, 52.8. **HRMS(ESI)** Calcd. for C₁₉H₁₈ClNO₇S (M+Na)⁺ 462.0385, found 462.0364.

Methyl 3-(1-(4-bromophenyl)-1,2-dimethoxy-2-oxoethyl)-2,3-dihydrobenzo[d]isothiazole-3-carboxylate 1,1-dioxide (6m).


White solid, *syn/anti* isomer (10:1) ratio.



syn-6m (58% yield): **¹H NMR** (400 MHz, Chloroform-*d*) δ 7.97 (d, *J*= 7.38 Hz, 1H), 7.73 (d, *J*= 6.70 Hz, 1H), 7.65 – 7.59 (m, 2H), 7.54 (d, *J*= 8.31 Hz, 2H), 7.46 (d, 2H), 5.85 (brs, 1H), 3.59 (s, 3H), 3.58 (s, 3H), 3.31 (s, 3H); **¹³C NMR** (101 MHz, Chloroform-*d*) δ 167.8, 167.6, 135.8, 134.0, 132.6, 132.5, 131.1, 130.8, 130.5, 129.3, 123.7, 120.7, 89.1, 73.4, 54.9, 54.1, 52.8. **HRMS(ESI)** Calcd. for C₁₉H₁₈BrNO₇S (M+Na)⁺ 505.9880, found 505.9860.

Methyl 3-(1-(4-chlorophenyl)-2-methoxy-1-((4-methylbenzyl)oxy)-2-oxoethyl)-2,3-dihydrobenzo[d]isothiazole-3-carboxylate 1,1-dioxide (6n).


White solid, *syn/anti* isomer (10:1) ratio.



syn-6n (63% yield): **¹H NMR** (400 MHz, Chloroform-*d*) δ 8.09 (t, *J*= 3.31 Hz, 1H), 7.74 (t, *J*= 3.95 Hz, 1H), 7.64 – 7.55 (m, 4H), 7.37 (d, *J*= 8.34 Hz, 2H), 7.25 (d, *J*= 5.97 Hz, 2H), 7.22 (d, *J*= 7.96 Hz, 2H), 5.82 (s, 1H), 4.49 (d, *J*= 11.32 Hz, 1H), 4.33 (d, *J*= 11.33 Hz, 1H), 3.57 (s, 3H), 3.53 (s, 3H), 2.40 (s, 3H); **¹³C NMR** (101 MHz, Chloroform-*d*) δ 167.8, 167.7, 137.7, 135.8, 135.5, 134.1, 133.9, 132.5, 132.2, 130.5, 130.4, 129.6, 129.3, 128.2, 127.1, 120.7, 88.8, 73.4, 68.8, 54.1, 52.8, 21.3. **HRMS(ESI)** Calcd. for C₂₆H₂₄ClNO₇S (M+H)⁺ 552.0854, found 552.0851.


Methyl 3-(1-(4-bromophenyl)-2-methoxy-1-((4-methylbenzyl)oxy)-2-oxoethyl)-2,3-dihydrobenzo[d]isothiazole-3-carboxylate 1,1-dioxide (6o).


White solid, *syn/anti* isomer (10:1) ratio.





syn-6o (58% yield): **¹H NMR** (400 MHz, Chloroform-*d*) δ 8.08 (t, *J*= 5.20 Hz, 1H), 7.74 (d, *J*= 4.33 Hz, 1H), 7.64 – 7.58 (m, 2H), 7.56 – 7.48 (m, 4H), 7.25 (d, *J*= 7.52 Hz, 2H), 7.21 (d, *J*= 7.94 Hz, 2H), 5.82 (s, 1H), 4.48 (d, *J*= 11.36 Hz, 1H), 4.33 (d, *J*= 11.35 Hz, 1H), 3.57 (s, 3H), 3.53 (s, 3H), 2.39 (s, 3H); **¹³C NMR** (101 MHz, Chloroform-*d*) δ 167.7, 167.6, 137.7, 135.8, 134.1, 133.8, 132.8, 132.5, 131.2, 130.7, 130.5, 129.6, 129.3, 127.1, 123.8, 120.7, 88.9, 73.4, 68.8, 54.1, 52.8, 21.3. **HRMS(ESI)** Calcd. for C₂₆H₂₄BrNO₇S (M+H)⁺ 596.0349, found 596.0353.


6. ^1H and ^{13}C NMR spectra for products 4 and 6















anti-4b





syn-4b







anti-4c




anti-4c





8.21
 8.19
 7.63
 7.61
 7.59
 7.52
 7.50
 7.49
 7.47
 7.45
 7.09
 6.92
 6.82
 6.80
 6.41
 6.39
 - 5.80





syn-4c





































syn-4k




syn-4k









-63.18




anti-4l





62.72





syn-4l





































anti-4s





anti-4s

























syn-6d





syn-6d

















syn-6j

